CohBar (CWBR) and Morphogenesis, Inc. Enter into Definitive Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunoth
May 23, 2023 7:31 AM EDTCombined company will operate under the name TuHURA Biosciences, Inc. and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET
MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:... More
